tumor response News
-
OncoImmunity starts a personalized cancer vaccine project with a Chinese biotech company
OncoImmunity teams up with an innovative China based high-tech biotechnology company that has developed a dendritic cell-based vaccine delivery platform. The Chinese vaccine company is developing a personalized cancer vaccine solution with its platform that promises to deliver potent anti-tumor immune responses in vaccinated patients. The collaboration will demonstrate the power of the ...
-
Precision therapeutics continues dedicated support to the NOCC `walk to break the silence`
Precision Therapeutics will sponsor the Pittsburgh Chapter of the National Ovarian Cancer Coalition's "Walk to Break the Silence" on Sunday, September 12, 2010. The walk, which takes place at the North Park Boathouse, is an optional 1 or 5 mile hike to benefit ovarian cancer awareness. Hoping that a great number of its employees will unite to help fortify the partnerships it has forged in ...
-
VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual Meeting
Median overall survival and 18-month overall survival data continue to show improvements over historical controls1 One patient remains on protocol progression-free beyond two years, with a sustained 93% tumor reduction relative to baseline Next steps : Recurrent GBM: randomized, controlled evaluation with potential to support accelerated approval application expected to initiate in Q3 2022 ...
-
Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced today that in preclinical studies its lead clinical compound, LB-100, a protein phosphatase (PP2A) inhibitor, was found to increase the responsiveness of diverse cancers to immunotherapy. In Nature Communications (15 Dec 2021), ...
-
Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer
Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology industry. As CDO, Chan will play a key leadership role in advancing Actym's pipeline of first-in-class, systemically administered therapeutics that re-program the immunosuppressive microenvironment in solid tumors. "Chan has significant ...
-
Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME
Company to host conference call on Tuesday, November 9 at 8:30 am EST Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells Objective responses (RECIST 1.1) observed in 8/16 patients (50%) across multiple solid cancer types, with 8/13 responders (62%) treated at dose levels 2 and 3 High T cell engraftment ...
-
Actym Therapeutics Announces Lead Candidate for Clinical Development, Presentation at SITC
Actym Therapeutics today announced that ACTM-838 has been selected as a lead clinical development candidate for the treatment of solid tumors. ACTM-838 is based on the company's immunotherapy platform called STACT (S. Typhimurium-Attenuated Cancer Therapy), which delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. ACTM-838 is a STACT strain that encodes ...
-
ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today provided an update on the development strategy for oncolytic virus ParvOryx, a wild type rat oncolytic parvovirus (H-1PV). So far, two Phase I/IIa clinical trials in recurrent glioblastoma (rGBM) and metastatic, inoperable pancreatic cancer have been completed successfully. Moreover, in a follow-up ...
-
Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Presented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced Solid Tumors, Showing Clinical Responses with Favorable Tolerability in PD-(L)1 Refractory Disease Expanded Ongoing Phase 1 Arm of RTX-240 + Pembrolizumab to Focus on Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) Dosing Patients in Phase 1 Clinical Trial of RTX-224 in Select ...
-
ORYX Confirms ParvOryx Mode of Action in Tumor Explant Model
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today reported new results on the mode of action of oncolytic virus ParvOryx in human ovarian cancer explants. ParvOryx, a wild type rat oncolytic parvovirus (H-1PV), had successfully completed two Phase I/IIa clinical trials in glioblastoma and pancreatic cancer, respectively. The new data show that ...
-
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector therapy Phase 2 to proceed with alternating 2-vector therapy in combination with pembrolizumab, which will help inform the randomized Phase 2 trial with pembrolizumab planned to start in the first half of 2023 Additional Phase 2 cohort will ...
-
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO
Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed anti-tumor activity in heavily pre-treated head and neck cancer patients Poster presentation to include data supporting recommended Phase 2 dose for alternating 2-vector HB-202/HB-201 and Phase 2 development plans in head and neck cancers HOOKIPA ...
-
Treos Bio Enters into Clinical Collaboration to Evaluate its Polypeptide Cancer Immunotherapy PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor
LONDON, July 7, 2021– Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop both precision off-the-shelf and personalized peptide cancer immunotherapies, today announced a clinical collaboration with Roche in which Treos will evaluate the combination of PolyPEPI1018, its lead product candidate, and ...
-
PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T-SIGn vector, NG-350A, to Re-Engineer Advanced Cancers
Key data from the first-in-human FORTITUDE trial shows that a single cycle of intravenous (IV) NG-350A drives dose-dependent increases in specific inflammatory biomarkers, consistent with the mechanism of the encoded anti- CD40 agonist. IV dosing of NG-350A led to elevations in IL-12, IFNγ and IL-17 that were higher and sustained for longer than those reported for systemic CD40 agonists. ...
-
Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting
Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 in Advanced Solid Tumors to be Presented in a Poster at the American Association of Cancer Research Annual Meeting on Tuesday, April 12, 2022, from 9:00 a.m. – 12:30 p.m. ET Management to Host Investor Webcast to Discuss RTX-240 Single-Agent Results in Advanced Solid Tumors and Acute Myeloid Leukemia (AML) Along with ...
-
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced the publication of preclinical data in the peer-reviewed journal Cancer Immunology, Immunotherapy, for its lead clinical oncology program, RTX-240, for the ...
-
Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
Transgene will discuss new immunogenicity and clinical data generated with TG4050 that reinforce the strong potential of this individualized immunotherapy: Relevant neoantigens could be identified in all evaluable patients and TG4050 induced tumor specific T cell responses against multiple of these patient-specific neoantigen targets. Early signs of clinical activity were observed with ...
By Transgene
-
VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma
FDA Orphan Drug Designation reflects urgent need for new therapies for glioblastoma (GBM) patients Next steps for development of VBI-1901 : Q3 2022: Expected initiation of randomized, controlled clinical study in recurrent GBM patients with potential to support accelerated approval application Q4 2022: Expected initiation of randomized, controlled evaluation in primary GBM patients as part ...
-
Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium
New Guardant Reveal™ data from interim analysis of COSMOS-CRC-01 demonstrates high performance for recurrence detection in early-stage colorectal cancer REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data highlighting the clinical utility of its liquid biopsy tests in the treatment and ...
-
Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
Armed Poxvirus selectively destroys tumor cells SAN FRANCISCO and YONGIN, South Korea, January 12, 2009 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), and its South Korean partner Green Cross Corp., today announced treatment of the first five patients in a Phase 2 primary liver cancer clinical trial using its targeted and armed poxvirus JX-594. No significant ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you